Shattuck Labs Inc
STTK2.280USD
+0.050+2.24%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
109.22MCap. mercado
PérdidaP/E TTM
Más Datos de Shattuck Labs Inc Compañía
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Información de la empresa
Símbolo de cotizaciónSTTK
Nombre de la empresaShattuck Labs Inc
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoDr. Taylor Schreiber, M.D., Ph.D.
Número de empleados44
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 09
Dirección500 W. 5Th Street
CiudadAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78701
Teléfono15129004690
Sitio Webhttps://www.shattucklabs.com/
Símbolo de cotizaciónSTTK
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoDr. Taylor Schreiber, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Otro
45.62%
Accionistas
Accionistas
Proporción
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Otro
45.62%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
28.47%
Investment Advisor/Hedge Fund
17.07%
Private Equity
13.16%
Corporation
12.56%
Investment Advisor
8.23%
Family Office
3.74%
Individual Investor
2.44%
Research Firm
1.52%
Otro
12.81%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
2023Q2
215
27.61M
64.91%
-8.42M
2023Q1
223
27.26M
64.10%
-8.88M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Prosight Capital
6.64M
13.86%
--
--
Mar 31, 2025
Redmile Group, LLC
5.54M
11.56%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
4.67M
9.76%
--
--
Mar 31, 2025
Hornblower Capital Holdings, LLC
2.89M
6.04%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
5.45%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.40M
5.01%
-7.92K
-0.33%
Mar 31, 2025
The Clark Estates Inc.
1.48M
3.08%
--
--
Mar 31, 2025
Pinnacle Associates Ltd.
1.30M
2.71%
-25.00K
-1.89%
Mar 31, 2025
683 Capital Management LLC
1.05M
2.19%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
